Osimertinib, a third-generation TKIs that originally invented to treat T790M-regulated resistance to first-generation TKIs, showed longer disease-free survival compared with placebo in patients with completely resected stage Ib-IIIa EGFR-mutated NSCLC as adjuvant therapy (Wu et al., 2020) and longer PFS and OS and a reduced risk of CNS metastases compared with first-generation TKIs for the treatment of EGFR-mutated advanced NSCLC (Ramalingam et al., 2020). Here, EGFR is linked to non-small cell lung carcinoma.